LOSARTAN POTASSIUM TABLETS, USP, 25 mg, a) 90-count (NDC: 13668-113-90), b) 1000-count (NDC: 1366...
FDA Drug Recall #D-1114-2019 — Class II — February 28, 2019
Recall Summary
| Recall Number | D-1114-2019 |
| Classification | Class II — Moderate risk |
| Date Initiated | February 28, 2019 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Torrent Pharma Inc. |
| Location | Basking Ridge, NJ |
| Product Type | Drugs |
| Quantity | 133,992 bottles |
Product Description
LOSARTAN POTASSIUM TABLETS, USP, 25 mg, a) 90-count (NDC: 13668-113-90), b) 1000-count (NDC: 13668-113-10), per bottle, Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India. For: Torrent Pharma, Inc, 150 Allen Road, Suite 102, Basking Ridge, NJ
Reason for Recall
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.
Distribution Pattern
Nationwide USA and Puerto Rico
Lot / Code Information
Count, lots, expiry: [90-count bottle ] Lots 4DU1E005, 4DU1E006, 4DU1E008, exp 1/31/2021; Lots 4DU1E007, exp 1/31/2021
Other Recalls from Torrent Pharma Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0455-2025 | Class II | Fluoxetine Tablets, USP, 20 mg, 30-count bottl... | May 27, 2025 |
| D-0456-2025 | Class II | Fluoxetine Tablets, USP, 20 mg, 28-count Carton... | May 27, 2025 |
| D-0365-2022 | Class II | Carbamazepine Tablets, USP 200 mg 100 Tablets R... | Dec 2, 2021 |
| D-0285-2022 | Class III | Telmisartan and Hydrochlorothiazide Tablets, US... | Dec 1, 2021 |
| D-1317-2020 | Class II | Carbamazepine Tablets, USP 200 mg, packaged in ... | May 11, 2020 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.